Abstract
Relevance. Palatoplasty is a technically demanding reconstructive surgery for congenital full-thickness defects of the palate, with more than 20% of cases reporting postoperative complications. The primary cause of these complications is chronic oral inflammation. To mitigate inflammatory reactions, medications with antibacterial, bactericidal, and antiseptic properties are employed. Given the age-specific characteristics of children and the presence of full-thickness palate defects, it is essential to administer anti-inflammatory medications in an adapted, prolonged, and safe form. Consequently, we have developed a prolonged-release phytocomplex in the form of lozenges.Purpose. To evaluate the effectiveness of a prolonged-release phytocomplex in preventing postoperative complications in children following palatoplasty.Materials and methods. This study presents clinical and laboratory examination data from 90 children aged 2.5 to 5 years with cleft palate who underwent palatoplasty, and 45 healthy children aged 3 to 8 years. The study involved measuring the levels of secretory immunoglobulin IgA in the oral fluid using the 'IgA Secretory ELISA-BEST' reagent kit, cytokines (interleukins-2, 4, 6), and gamma-interferon through enzyme immunoassay with kits from 'Vector Best' (Russia), and lysozyme using the Lysozyme-96 kit.Results. It was observed that following the use of the prolonged-release phytocomplex, the levels of sIgA, lysozyme, and interleukins-2, 4, and 6 in the oral fluid of the children were significantly elevated compared to the control group. Additionally, the gamma-interferon levels returned to normal.Conclusion. The findings of this study demonstrate the positive antimicrobial, anti-inflammatory, and woundhealing effects of the developed prolonged-release phytocomplex in the form of lozenges.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call